Current treatments for diabetic complication macular edema still not effective enough
While there have been several significant steps forward when it comes to treating diabetes complication diabetic macular edema (DME) this year, current therapies are still not effective enough.
Data and analytics company GlobalData notes that not only is there still a surplus of unmet needs, but current therapies still have quite a heavy treatment burden. Further, several key opinion leaders (KOLs) interviewed by GlobalData spoke out to say that a significant number of DME patients do not respond well to current standard-of-care therapies.
According to GlobalData’s latest report, ‘Diabetic Macular Edema Drugs in Development by Stages’, two DME drugs have been approved in 2022 so far: Roche’s (ROG: SIX) Vabysmo (faricimab-svoa) in January and Novartis’ (NOVN: VX) Beovu (brolucizumab) in March. This has heightened competition within the international DME market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze